EFSA Journal (Oct 2021)

Maximum levels of cross‐contamination for 24 antimicrobial active substances in non‐target feed. Part 13: Diaminopyrimidines: trimethoprim

  • EFSA Panel on Biological Hazards (BIOHAZ),
  • Konstantinos Koutsoumanis,
  • Ana Allende,
  • Avelino Alvarez‐Ordóñez,
  • Declan Bolton,
  • Sara Bover‐Cid,
  • Marianne Chemaly,
  • Robert Davies,
  • Alessandra De Cesare,
  • Lieve Herman,
  • Friederike Hilbert,
  • Roland Lindqvist,
  • Maarten Nauta,
  • Giuseppe Ru,
  • Marion Simmons,
  • Panagiotis Skandamis,
  • Elisabetta Suffredini,
  • Dan I Andersson,
  • Vasileios Bampidis,
  • Johan Bengtsson‐Palme,
  • Damien Bouchard,
  • Aude Ferran,
  • Maryline Kouba,
  • Secundino López Puente,
  • Marta López‐Alonso,
  • Søren Saxmose Nielsen,
  • Alena Pechová,
  • Mariana Petkova,
  • Sebastien Girault,
  • Alessandro Broglia,
  • Beatriz Guerra,
  • Matteo Lorenzo Innocenti,
  • Ernesto Liébana,
  • Gloria López‐Gálvez,
  • Paola Manini,
  • Pietro Stella,
  • Luisa Peixe

DOI
https://doi.org/10.2903/j.efsa.2021.6865
Journal volume & issue
Vol. 19, no. 10
pp. n/a – n/a

Abstract

Read online

Abstract The specific concentrations of trimethoprim in non‐target feed for food‐producing animals below which there would not be an effect on the emergence of, and/or selection for, resistance in bacteria relevant for human and animal health, as well as the specific antimicrobial concentrations in feed which have an effect in terms of growth promotion/increased yield were assessed by EFSA in collaboration with EMA. Details of the methodology used for this assessment, associated data gaps and uncertainties, are presented in a separate document. To address antimicrobial resistance, the Feed Antimicrobial Resistance Selection Concentration (FARSC) model developed specifically for the assessment was applied. The FARSC for trimethoprim was estimated. Uncertainties and data gaps associated to the levels reported were addressed. To address growth promotion, data from scientific publications obtained from an extensive literature review were used. No suitable data for the assessment were available. It was recommended to perform further studies to supply more diverse and complete data related to the requirements for calculation of the FARSC for trimethoprim.

Keywords